[1]
RavasioR., AntonelliS., MaiorinoA., CostanzoA. and LosiS. 2019. Cost per responder for ixekizumab and other biologic drugs approved for the treatment of moderate-to-severe plaque psoriasis in Italy. Global & Regional Health Technology Assessment. 6, 1 (Jan. 2019). DOI:https://doi.org/10.33393/grhta.2019.468.